Stock info Kuros Biosciences | Filter  Basic-Info

Kuros Biosciences

The past year was a good year for Kuros Biosciences investors

Over the period from December 2015 till December 2016 the stock lost around 63 percent. Over the past 5 years the stock lost a massive -92,68 percent. Kuros Biosciences's revenues between 2011 and 2015 were far from constant and moved between 1,1 million CHFF and 6,36 million CHFF. Kuros Biosciences's net incomes between 2011 and 2015 were very volatile through the time and moved between -16,49 million CHFF and 6,23 million CHFF.

The period from 2006 till the end of 2016 the international sector gained around 59 percent. As from 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

Over the past 5 years the Swiss company paid out dividends.

At the end of 2015 around 860 people were employed at Kuros Biosciences.

Kuros Biosciences financed with a quite low debt position

At the end of 2015 the biotech company's balance sheet was worth 3,26 million CHFF. Of the total balance sheet 2,59 million CHFF (79,45 percent) was financed by debt. At the end of 2015 the biotech company's stock was traded with a price/earnings-ratio 3. So the stock' value was 3 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the Swiss stock can be seen as a value stock.

At the end of 2015 the biotech company's market capitalization (the number of shares times the market price) equaled around 31,06 million CHFF. At the end of 2015 around 79,65 million stocks were listed.

On this page you can find all Kuros Biosciences's financial reports. More information about Kuros Biosciences can be found it's website. .